Botulinum toxin A versus microwave thermolysis for primary axillary hyperhidrosis: A randomized controlled trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Botulinum toxin A versus microwave thermolysis for primary axillary hyperhidrosis : A randomized controlled trial. / Grove, Gabriela Lladó; Togsverd-Bo, Katrine; Zachariae, Claus; Haedersdal, Merete.
In: JAAD International, Vol. 15, 2024, p. 91-99.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Botulinum toxin A versus microwave thermolysis for primary axillary hyperhidrosis
T2 - A randomized controlled trial
AU - Grove, Gabriela Lladó
AU - Togsverd-Bo, Katrine
AU - Zachariae, Claus
AU - Haedersdal, Merete
N1 - Publisher Copyright: © 2024 American Academy of Dermatology, Inc.
PY - 2024
Y1 - 2024
N2 - Background: Botulinum toxin A (BTX) and microwave thermolysis (MWT) represent 2 treatment modalities for axillary hyperhidrosis with different procedural and efficacy profiles. Objective: To compare long-term outcomes following BTX vs MWT treatment of axillary hyperhidrosis. Methods: A prospective, randomized, within-patient, controlled trial, treating axillary hyperhidrosis with contralateral BTX and MWT. Objective sweat measurement and patient-reported outcome measures for sweat and odor were collected at baseline, 6-month and 1-year follow-up (6M/1YFU). Hair reduction and patient treatment preference was also assessed. Results: Sweat reduction was significant (all P <.01) for both interventions throughout the study. Objectively, sweat reduction was equal at 1-year FU (ΔP =.4282), but greater for BTX than MWT at 6-month FU (ΔP =.0053). Subjective sweat assessment presented comparable efficacy (6MFU: ΔP =.4142, 1YFU: ΔP =.1025). Odor reduction was significant (all P <.01) following both interventions, whereas only sustaining for MWT (6MFU: ΔP =.6826, 1YFU: ΔP =.0098). Long-term, hair reduction was visible after MWT, but not BTX (ΔP ≤.0001), and MWT was preferred by the majority of patients (76%). Limitations: The intrinsic challenges in efficacy assessment. Conclusion: This study exhibited BTX and MWT with similar sweat reduction, but distinguishable odor and hair reduction at 1-year FU. These findings support individualized treatment approaches for axillary hyperhidrosis based on patient-specific symptoms and preferences.
AB - Background: Botulinum toxin A (BTX) and microwave thermolysis (MWT) represent 2 treatment modalities for axillary hyperhidrosis with different procedural and efficacy profiles. Objective: To compare long-term outcomes following BTX vs MWT treatment of axillary hyperhidrosis. Methods: A prospective, randomized, within-patient, controlled trial, treating axillary hyperhidrosis with contralateral BTX and MWT. Objective sweat measurement and patient-reported outcome measures for sweat and odor were collected at baseline, 6-month and 1-year follow-up (6M/1YFU). Hair reduction and patient treatment preference was also assessed. Results: Sweat reduction was significant (all P <.01) for both interventions throughout the study. Objectively, sweat reduction was equal at 1-year FU (ΔP =.4282), but greater for BTX than MWT at 6-month FU (ΔP =.0053). Subjective sweat assessment presented comparable efficacy (6MFU: ΔP =.4142, 1YFU: ΔP =.1025). Odor reduction was significant (all P <.01) following both interventions, whereas only sustaining for MWT (6MFU: ΔP =.6826, 1YFU: ΔP =.0098). Long-term, hair reduction was visible after MWT, but not BTX (ΔP ≤.0001), and MWT was preferred by the majority of patients (76%). Limitations: The intrinsic challenges in efficacy assessment. Conclusion: This study exhibited BTX and MWT with similar sweat reduction, but distinguishable odor and hair reduction at 1-year FU. These findings support individualized treatment approaches for axillary hyperhidrosis based on patient-specific symptoms and preferences.
KW - botulinum toxin
KW - bromhidrosis
KW - hyperhidrosis
KW - individualized treatment
KW - microwave thermolysis
KW - osmidrosis
KW - personalized therapy
KW - PROMs
KW - QoL
KW - randomized controlled trial
KW - RCT
U2 - 10.1016/j.jdin.2023.12.011
DO - 10.1016/j.jdin.2023.12.011
M3 - Journal article
C2 - 38495540
AN - SCOPUS:85187359531
VL - 15
SP - 91
EP - 99
JO - JAAD International
JF - JAAD International
SN - 2666-3287
ER -
ID: 385584707